The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Jacquie Chirgwin; Zhuoxin Sun; Ian Smith; Karen N Price; Beat Thurlimann; Bent Ejlertsen; Herve Bonnefoi; Meredith M Regan; Aron Goldhirsch; Alan S Coates

doi:10.1007/s10549-011-1741-6

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Jacquie Chirgwin, Zhuoxin Sun, Ian Smith, Karen N Price, Beat Thurlimann, Bent Ejlertsen, Herve Bonnefoi, Meredith M Regan, Aron Goldhirsch, Alan S Coates

Eastern Health Clinical School

Research output: Contribution to journal › Article › Research › peer-review

13 Citations (Scopus)

Original language	English
Pages (from-to)	295 - 306
Number of pages	12
Journal	Breast Cancer Research and Treatment
Volume	131
Issue number	1
DOIs	https://doi.org/10.1007/s10549-011-1741-6
Publication status	Published - 2012

Access to Document

10.1007/s10549-011-1741-6

Cite this

Chirgwin, J., Sun, Z., Smith, I., Price, K. N., Thurlimann, B., Ejlertsen, B., Bonnefoi, H., Regan, M. M., Goldhirsch, A., & Coates, A. S. (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131(1), 295 - 306. https://doi.org/10.1007/s10549-011-1741-6

@article{f2c252ecd64e430eb0ab24b6a3c986cf,

title = "The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause",

author = "Jacquie Chirgwin and Zhuoxin Sun and Ian Smith and Price, {Karen N} and Beat Thurlimann and Bent Ejlertsen and Herve Bonnefoi and Regan, {Meredith M} and Aron Goldhirsch and Coates, {Alan S}",

year = "2012",

doi = "10.1007/s10549-011-1741-6",

language = "English",

volume = "131",

pages = "295 -- 306",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "1",

}

Chirgwin, J, Sun, Z, Smith, I, Price, KN, Thurlimann, B, Ejlertsen, B, Bonnefoi, H, Regan, MM, Goldhirsch, A & Coates, AS 2012, 'The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause', Breast Cancer Research and Treatment, vol. 131, no. 1, pp. 295 - 306. https://doi.org/10.1007/s10549-011-1741-6

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. / Chirgwin, Jacquie; Sun, Zhuoxin; Smith, Ian et al.
In: Breast Cancer Research and Treatment, Vol. 131, No. 1, 2012, p. 295 - 306.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

AU - Chirgwin, Jacquie

AU - Sun, Zhuoxin

AU - Smith, Ian

AU - Price, Karen N

AU - Thurlimann, Beat

AU - Ejlertsen, Bent

AU - Bonnefoi, Herve

AU - Regan, Meredith M

AU - Goldhirsch, Aron

AU - Coates, Alan S

PY - 2012

Y1 - 2012

UR - http://www.springerlink.com/content/j77251040u0t5432/fulltext.pdf

U2 - 10.1007/s10549-011-1741-6

DO - 10.1007/s10549-011-1741-6

M3 - Article

SN - 0167-6806

VL - 131

SP - 295

EP - 306

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Access to Document

Other files and links

Cite this